Taking on challenging targets: making MYC druggable.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The proto-oncogene c-MYC (MYC) is a transcription factor deregulated in aggressive human malignancies.
• MYC influences critical cellular processes including proliferation, differentiation, metabolism, and survival.
• Elevated MYC expression correlates with aggressive tumor phenotypes and poorer disease-free survival.

Purpose of the Study:

• To review the progress in developing targeted therapies for MYC-overexpressing tumors.
• To highlight MYC as a challenging but critical therapeutic target in oncology.

Main Methods:

• Review of preclinical animal and cell-based model systems.
• Analysis of ongoing research into MYC-dependent tumorigenesis and therapeutic strategies.
• Investigation of MYC overexpression and gene signatures as potential clinical biomarkers.

Main Results:

• MYC deregulation is a hallmark of aggressive cancers, driving high proliferation and poor prognosis.
• Despite extensive research, no targeted therapies are currently available for MYC-driven tumors.
• Preclinical models are crucial for understanding MYC's role and developing treatment strategies.

Conclusions:

• Targeting MYC-overexpressing tumors presents a significant challenge in cancer therapy.
• Ongoing research shows promise in developing novel therapeutic strategies against this previously undruggable target.
• Understanding MYC biology is key to advancing treatments for aggressive cancers.